¾Ç¼º Ç÷¾× Áúȯ ¼Ò¾Æµé¿¡¼­ ¹ß»ýÇÑ ÁÖÀÇ·Â °áÇÌ °úÀ× ÇൿÀå¾ÖÀÇ Æ¯¼º
Clinical Characteristics of Attention Deficit Hyperactivity Disorder in Childhood Malignant Hematologic Diseases

´ëÇѼҾƽŰæÇÐȸÁö 2014³â 22±Ç 2È£ p.63 ~ p.68

¹è¶ó¹Ì(Pae Ra-Mee) - °¡Å縯´ëÇб³ Àǰú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
¹Ú¼±¿µ(Park Sun-Young) - °¡Å縯´ëÇб³ Àǰú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
ÇÑÁöÀ±(Han Ji-Yoon) - °¡Å縯´ëÇб³ Àǰú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
ÀÌÀç¿í(Lee Jae-Wook) - °¡Å縯´ëÇб³ Àǰú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
Á¤³«±Õ(Chung Nack-Gyun) - °¡Å縯´ëÇб³ Àǰú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
Á¶ºó(Cho Bin) - °¡Å縯´ëÇб³ Àǰú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
±èÇбâ(Kim Hack-Ki) - °¡Å縯´ëÇб³ Àǰú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
ÀÌÀα¸(Lee In-Goo) - °¡Å縯´ëÇб³ Àǰú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç

Abstract

¸ñÀû: ¾Ç¼º Ç÷¾×ÁúȯÀ» Ä¡·á ¹ÞÀº ȯÀÚ¿¡¼­ ADHDÀÇ À¯º´·üÀ» ¾Ë¾Æº¸°í, ADHD°¡ Áߺ¹µÇ¾î Àִ ȯÀÚ¿Í ADHD°¡ Áߺ¹µÇÁö ¾Ê´Â ȯÀÚ¸¦ ºñ±³ ºÐ¼®ÇÏ¿© Ư¡°ú ¿¬°ü¼ºÀ» ¾Ë¾Æ º» ÈÄ, ÀÌ °á°ú¸¦ ADHD°¡ Áߺ¹µÇ¾î Àִ ȯÀڵ鿡°Ô Àû¿ëÇÏ¿© ¾Ç¼º Ç÷¾×Áúȯ ȯÀÚ¿¡¼­ ADHD ¹ß»ýÀ» ¿¹ÃøÇÏ¿© Ä¡·á¿¡ µµ¿òÀ» ÁÖ±â À§ÇÏ¿© ÀÌ ¿¬±¸¸¦ °èȹÇÏ¿´´Ù.

¹æ¹ý: 2009³â 3¿ùºÎÅÍ 2012³â 5¿ù±îÁö °¡Å縯´ëÇб³ ¼­¿ï¼º¸ðº´¿ø ¼Ò¾Æ Ç÷¾× ºÐ°ú¿¡ µî·ÏµÈ ȯÀÚµé Áß ÃÖ¼Ò 1³â ÀÌ»ó ÃßÀû °üÂûÀÌ °¡´ÉÇÏ¿´´ø 6¼¼¿¡¼­ 15¼¼±îÁöÀÇ È¯ÀÚ 172¸í ÀÇ ¾Ç¼º Ç÷¾× Áúȯ ȯÀÚµéÀ» ´ë»óÀ¸·Î ADHD Áø´Ü °Ë»ç¸¦ ½ÃÇà ÇÏ¿´´Ù. ÀÌÈÄ ³ªÀÌ, ¼ºº°, ADHD ¾ÆÇüº° ºÐ·ù, Ç÷¾×Áúȯ Á¾·ù, Ç÷¾× Áúȯ ¹ßº´¿¬·É, È­Çпä¹ý Ä¡·á À¯¹«, Àç¹ß¿¡ ´ëÇÏ¿© ºÐ¼®ÇÏ¿´´Ù. ±×¸®°í ´ë»ó ȯÀÚ¸¦ ADHD°¡ Áߺ¹µÈ ±º°ú Áߺ¹µÇÁö ¾ÊÀº ±ºÀ¸·Î ³ª´©¾î ³ªÀÌ, ¼ºº°, ADHD ¾ÆÇüº° ºÐ·ù, Ç÷¾×Áúȯ Á¾·ù, Ç÷¾× Áúȯ ¹ßº´¿¬·É, È­Çпä¹ý Ä¡·á ¹× Àç¹ß À¯¹«¿¡ µû¶ó ºñ±³ ºÐ¼®ÇÏ¿´´Ù.

°á°ú: ´ë»ó ȯÀÚ 172¸í Áß ADHD°¡ Áߺ¹µÈ ȯÀÚ´Â 51¸íÀ¸·Î À¯º´·üÀº 29.6% À̾ú´Ù. ¼ºº°(³²ÀÚ), Ç÷¾× Áúȯ ¹ßº´ ¿¬·É(5¼¼ ÀÌÇÏ) ±×¸®°í È­Çпä¹ýÀ» ½ÃÇàÇÑ °æ¿ì°¡ ADHD°¡ Áߺ¹µÇÁö ¾ÊÀº ±º¿¡ ºñÇØ ADHD Áߺ¹±º¿¡¼­ À¯ÀÇÇÏ°Ô ³ô¾Ò´Ù(P<0.05). ADHD°¡ ¹ß»ýÇÒ È®·üÀº ³²ÀÚ°¡ ¿©ÀÚ¿¡ ºñÇØ ¾à 2.9¹è ³ô¾Ò´Ù(P=0.005). ¾Ç¼º Ç÷¾× ÁúȯÀÌ 11¼¼ À̻󿡼­ ¹ßº´ÇÑ °æ¿ì¿¡ ºñÇØ 5¼¼ ÀÌÇÏ¿¡¼­ ¹ßº´ÇÑ °æ¿ì´Â ADHD°¡ ¹ß»ýÇÒ È®·üÀÌ ¾à 3.3¹è ³ô¾Ò´Ù(P=0.007). ±×¸®°í È­ÇÐÄ¡·á¸¦ ¹ÞÀº ȯÀÚ¿¡¼­ ADHD°¡ ¹ß»ýÇÒ È®·üÀº ¾à 3.4¹è ³ô¾Ò´Ù(P=0.023).

°á·Ð: º» ¿¬±¸´Â ¾Ç¼º Ç÷¾× ÁúȯÀÌ ADHD¿Í ¿¬°ü¼ºÀÌ ÀÖ´Ù´Â °ÍÀ» º¸¿© ÁØ´Ù. ¶ÇÇÑ, ³²¼º, 5¼¼ ÀÌÇÏÀÇ ¹ßº´¿¬·É, È­ÇÐ ¿ä¹ý Ä¡·áÀÇ »ç¿ëµéÀÌ ADHD¸¦ ¿¹ÃøÇÏ´Â µ¥ µµ¿ò µÉ ¼ö ÀÖ¾ú´Ù. ÀÌ¿¡ µû¸¥ ADHDÀÇ Á¶±â ¹ß°ß°ú Ä¡·á´ëÃ¥ÀÇ ¼ö¸³ÀÌ ÇÊ¿äÇÒ °ÍÀ¸·Î º¸ÀδÙ.
Purpose: The purpose of this study is to identify the prevalence of attention-deficit hyperactivity disorder (ADHD) among children treated for childhood malignant hematologic diseases, and determine the different characteristics of the patients with ADHD as opposed to the patients without ADHD, which will help to predict the development of ADHD and to help treat them.

Methods: 172 patients diagnosed as childhood malignant hematologic diseases went through the test battery including diagnostic criteria for ADHD in pediatric neurology department of Seoul St. Mary`s hospital from March 2009 to May 2012. Age, sex, ADHD type, hematologic diseases type, age at onset of hematologic diseases, treatment with/without chemotherapy and relapse were investigated. These data were compared between the groups of the patients without ADHD and with ADHD.

Results: Out of 172 patients, Fifty one patients (29.6%) had both ADHD and childhood malignant hematologic diseases. Sex (male), age at onset of hematologic diseases (¡Â5 years) and treatment(with chemotherapy) was significantly higher in the patients with ADHD than the patients without ADHD (P£¼0.05). Male had about 2.9 fold increased risk for ADHD compared to female (P=0.005). The patients ¡Â5 years of age at onset had about 3.3 fold increased risk for ADHD compared to the patients ¡Ã11 years (P=0.007). The patients with chemotherapy had about 3.4 fold increased risk for ADHD compared to the patients without chemotherapy (P=0.023).

Conclusion: This study showed childhood malignant hematologic disorders has significant correlation with ADHD. In addition, Male, ¡Â5 years of age at onset and use of chemotherapy in the patients can be necessary to predict ADHD. Therefore, early detection and establishment of the countermeasures for ADHD are necessary.

Ű¿öµå

Attention Deficit Hyperactivity Disorder, Hematologic Diseases
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Ű¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆÇ³âµµ(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå